Pliant Therapeutics (PLRX) Accumulated Depreciation & Amortization (2019 - 2025)
Pliant Therapeutics (PLRX) has disclosed Accumulated Depreciation & Amortization for 7 consecutive years, with $10.9 million as the latest value for Q4 2025.
- On a quarterly basis, Accumulated Depreciation & Amortization rose 0.57% to $10.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.9 million, a 0.57% increase, with the full-year FY2025 number at $10.9 million, up 0.57% from a year prior.
- Accumulated Depreciation & Amortization was $10.9 million for Q4 2025 at Pliant Therapeutics, down from $11.3 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $11.3 million in Q1 2025 to a low of $4.2 million in Q2 2021.
- A 5-year average of $7.9 million and a median of $7.3 million in 2023 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 49.52% in 2021, then rose 0.57% in 2025.
- Pliant Therapeutics' Accumulated Depreciation & Amortization stood at $5.0 million in 2021, then soared by 36.3% to $6.8 million in 2022, then grew by 26.91% to $8.7 million in 2023, then increased by 24.48% to $10.8 million in 2024, then increased by 0.57% to $10.9 million in 2025.
- Per Business Quant, the three most recent readings for PLRX's Accumulated Depreciation & Amortization are $10.9 million (Q4 2025), $11.3 million (Q1 2025), and $10.8 million (Q4 2024).